Summary

Anthem Biosciences Limited concluded FY26 on a strong note, reporting consolidated Revenue from Operations of ₹21,243 Mn, an increase of 15.2% year-on-year, with Q4FY26 being its highest revenue quarter ever at ₹6,109 Mn. The company demonstrated significant profitability improvements, with full-year EBITDA growing by 30.8% to ₹9,896 Mn and Profit After Tax (PAT) surging by 31.1% to ₹5,918 Mn, achieving healthy EBITDA margins of 43.4% and PAT margins of 26.0% respectively. Q4FY26 also saw remarkable growth in profitability, with EBITDA up 52.2% and PAT up 129.8% year-on-year. Chairman, MD, and CEO Ajay Bhardwaj highlighted the company's prudent cost management and focus on long-term value creation as key drivers for expanding profitability while delivering sustainable growth across all business segments.

Key Highlights

1. 1

   Anthem Biosciences Limited achieved a consolidated Revenue from Operations of ₹21,243 Mn for FY26, representing a 15.2% year-on-year growth, significantly driven by its CRDMO business which contributed ₹17,727 Mn.

2. 2

   The company reported a strong full-year EBITDA of ₹9,896 Mn, growing by 30.8% year-on-year, alongside robust EBITDA margins of 43.4%.

3. 3

   Profit After Tax (PAT) for FY26 increased by 31.1% year-on-year to ₹5,918 Mn, with PAT margins at 26.0%.

4. 4

   Q4FY26 marked the company's highest revenue quarter ever, with consolidated Revenue from Operations reaching ₹6,109 Mn, up 26.4% year-on-year.

5. 5

   For Q4FY26, EBITDA surged by 52.2% year-on-year to ₹3,184 Mn, while Profit After Tax (PAT) saw an impressive 129.8% year-on-year growth to ₹1,898 Mn, achieving EBITDA and PAT margins of 48.1% and 28.7% respectively.

6. 6

   The company maintained a healthy financial position, reporting a Net Cash position of ₹13,743 Mn as of March 31, 2026.